Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug –drug interaction predictions using a PBPK approach

ConclusionsThe posaconazole PBPK models were developed and clinically verified. Predictions using the robust PBPK model confirmed the venetoclax label recommendation of 70 mg in the presence of posaconazole at doses up to 500 mg QD.

http://link.springer.com/10.1007/s00280-020-04179-w

Source: Cancer Chemotherapy and Pharmacology - January 4, 2021 Category: Cancer & Oncology Source Type: research